Deutsche Bank AG Purchases 22,820 Shares of InMode Ltd. (NASDAQ:INMD)

Deutsche Bank AG raised its position in InMode Ltd. (NASDAQ:INMD) by 52.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 66,700 shares of the healthcare company’s stock after acquiring an additional 22,820 shares during the period. Deutsche Bank AG owned approximately 0.10% of InMode worth $1,114,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its holdings in shares of InMode by 2.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,266,618 shares of the healthcare company’s stock valued at $37,853,000 after purchasing an additional 50,200 shares during the last quarter. LSV Asset Management increased its position in InMode by 0.4% during the 4th quarter. LSV Asset Management now owns 1,715,071 shares of the healthcare company’s stock valued at $28,642,000 after buying an additional 6,300 shares in the last quarter. JPMorgan Chase & Co. raised its stake in InMode by 4.4% in the fourth quarter. JPMorgan Chase & Co. now owns 1,084,241 shares of the healthcare company’s stock valued at $18,107,000 after buying an additional 45,638 shares during the last quarter. Northern Trust Corp raised its stake in InMode by 17.0% in the fourth quarter. Northern Trust Corp now owns 658,154 shares of the healthcare company’s stock valued at $10,991,000 after buying an additional 95,652 shares during the last quarter. Finally, River Road Asset Management LLC acquired a new stake in InMode in the fourth quarter worth about $8,572,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Trading Down 0.7%

Shares of NASDAQ:INMD opened at $14.23 on Monday. InMode Ltd. has a twelve month low of $13.68 and a twelve month high of $19.85. The company has a market cap of $989.82 million, a PE ratio of 6.06 and a beta of 2.02. The company’s 50 day moving average is $15.61 and its 200 day moving average is $17.20.

InMode (NASDAQ:INMD) last released its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.14). InMode had a return on equity of 18.25% and a net margin of 45.91%. The business had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same quarter in the previous year, the company earned $0.32 EPS. The firm’s revenue was down 3.0% compared to the same quarter last year. Equities research analysts predict that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on INMD shares. BTIG Research downgraded shares of InMode from a “buy” rating to a “neutral” rating in a report on Tuesday, April 29th. Canaccord Genuity Group dropped their target price on shares of InMode from $17.00 to $15.00 and set a “hold” rating on the stock in a research report on Tuesday, April 29th. UBS Group cut their price target on shares of InMode from $19.00 to $16.25 and set a “neutral” rating on the stock in a research note on Tuesday, April 29th. Jefferies Financial Group lowered their price objective on shares of InMode from $16.00 to $15.00 and set a “hold” rating for the company in a research note on Monday, April 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Monday, April 28th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $18.54.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.